Literatur
-
01
Agnelli G .
Gallus A .
Goldhaber SZ .
et al .
Treatment of proximal deep-vein thrombosis with the oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939): the ODIXa-CVT (Oral Direct Factor Xa Inhibitior BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
Circulation.
2007;
116: (2)
180-187
-
02
Büller HR .
Once-daily treatment with an oral, direct Factor Xa inhibitor - rivaroxaban (Bay 59-7939) in patients with acute, symptomatic deep vein thrombosis. The EINSTEIN-DVT dose-finding study.
Eur Heart J.
2006;
27: (Abstract Suppl)
761
-
03 Lassen MR . Turpie AGG . Rosencher N . et al . Rivaroxaban - an oral, direct Factor Xa inhibitor - for the prevention of venous thromboembolism in total knee replacement surgery: results of the RECORD3 study. Oral presentation at the XXIst Congress of the International Society on Thrombosis and Haemostatis, Geneva, Switzerland, 6-12 Juli 2007.
1 REgulation of Coagulation in major Orthopaedic surgery reducing the Risk of DVT and pulmonary embolism
2 Oral Direct Factor Xa Inhibitor BAY 59-7939 in patients with acute symptomatic Deep-Vein Thrombosis
3 Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis without symptomatic pulmonary embolism
